The LynxDx leadership team. In the front row (from left to right) are: Spencer Heaton, Chief Medical and Commercial Officer; Steve Riggs, President; and Jeff Crays, Chief Technology Officer. In the ...

Researchers have developed a simple new tool that can identify the risk level of metastatic prostate cancer patients earlier. At the time of diagnosis, the test can predict how well the patient will ...

Prostate cancer is the second most common form of cancer found in men worldwide, affecting one out of nine at some point in their lives. It’s also the second leading cause of cancer death among men in ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

For decades, the story of prostate cancer screening has been dominated by three letters: P-S-A. The Prostate-Specific Antigen blood test is the first line of defense for millions of men. Yet, for all ...

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI diagnostic tool that can help lighten the burden.

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

“With this test, it could be possible to turn the tide on prostate cancer. We have shown that a relatively simple, inexpensive spit test to identify men of European heritage at higher risk due to ...